



HAL
open science

Multiomics Blood Biomarkers Predict Alzheimer from predementia with High Specificity

Benoit Souchet, Alkéos Michaïl, Maud Heuillet, Aude Dupuy-gayral, Eloi Haudebourg, Catherine Pech, Antoine Berthemy, Baptiste Billoir, François Autelitano, Juan Fortea, et al.

► To cite this version:

Benoit Souchet, Alkéos Michaïl, Maud Heuillet, Aude Dupuy-gayral, Eloi Haudebourg, et al.. Multiomics Blood Biomarkers Predict Alzheimer from predementia with High Specificity. *Alzheimer's & Dementia: the Journal of the Alzheimer's Association*, 2023, 19 (S24), pp.e082707. 10.1002/alz.082707. hal-04522821

HAL Id: hal-04522821

<https://hal.science/hal-04522821v1>

Submitted on 27 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

BIOMARKERS (NON-NEUROIMAGING)

Multiomics Blood Biomarkers Predict Alzheimer from predementia with High Specificity

Benoit Souchet¹ | Alkéos Michail¹ | Maud Heuillet² | Aude Dupuy-Gayral² |
 Eloi Haudebourg² | Catherine Pech² | Antoine Berthemy² | Baptiste Billoir¹ |
 François Autelitano² | Juan Fortea³ | Christopher J Fowler⁴ | Suman Jayadev⁵ |
 Alberto Lleo³ | Colin L Masters⁴ | Francois Mouton-Liger⁶ | Claire Paquet⁶ |
 Jerome Braudeau¹

¹AgenT SAS, Evry, France

²Evotec (France) SAS, Toulouse, France

³Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

⁴The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia

⁵University of Washington, Seattle, WA, USA

⁶Cognitive Neurology Center, Hôpital Lariboisière-Fernand Widal APHP, Paris, France

Correspondence

Jerome Braudeau, AgenT SAS, Evry France.

Email: jerome.braudeau@agent-biotech.com

Abstract

Background: The core criteria for mild cognitive impairment (MCI) or dementia due to Alzheimer's disease (AD) is based in part on cognitive criteria and biological evidence of at least moderately frequent amyloid plaques (Albert et al., 2011; McKhann et al., 2011). They predict AD among cognitively impaired patients with high sensitivity but low specificity (Kokkinou et al. 2021; Martinez et al. 2017; Ritchie et al. 2014): up to 25% of amyloid-positive patients would be misdiagnosed as AD while suffering from another brain disorder. Therefore, there is a need to develop new biomarkers with high specificity to facilitate earlier diagnosis, rapid therapeutic intervention and monitoring of clinical trials.

Method: Targeted mass spectrometry assays were developed for 81 blood biomarkers (45 proteins and 36 metabolites) pre-identified in AAV-AD rats (Audrain et al. 2018). 345 cognitively impaired participants (193 MCI and 152 demented) were collected in plasma at baseline and followed clinically from 1 to 13 years. Participants' diagnosis (AD, or non-AD) was established at the last clinical visit based on cognitive diagnosis standard for each brain disorder subtype. 82.9% of participants had available amyloid status at baseline, 61.9% were determined as amyloid positive. Each clinical group contained amyloid positive and negative participants. Predictive machine learning models for AD participants (n = 123 Prodromal AD, n = 126 AD dementia) among individuals with Non-AD brain disorder (Non-AD, n = 96) was developed. The training dataset (70%) aimed to select the biomarkers subset, train the algorithm, and define the cut-off. External test dataset (30%) aimed to validate in blind the locked predictive model.

Result: With 19 blood biomarkers and age, the model predicted AD participants (n = 41 Prodromal AD, n = 43 AD dementia) from non-AD participants (n = 25) with 92.0% specificity and 52.4% sensitivity during external validation (AUROC = 71.8%, p = 0.001). When amyloid status (CSF or PET) and this predictive ML model were applied

in series, and participants positive for both were predicted as AD, 100% specificity and 39.7% sensitivity were achieved.

Conclusion: Multiomics blood peripheral biomarkers predicted AD patients among cognitively impaired population with low FPR. In combination with amyloid screening, these biomarkers could identify a nearly pure AD population.